Skip to main content
Clinical Trials/NL-OMON50135
NL-OMON50135
Not yet recruiting
Not Applicable

Cardiomyopathy and heart failure risk after treatment for Hodgkin lymphoma or aggressive B cell non-Hodgkin lymphoma - CRYSTAL case-control

ederlands Kanker Instituut0 sites800 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
cardiomyopathy
Sponsor
ederlands Kanker Instituut
Enrollment
800
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
ederlands Kanker Instituut

Eligibility Criteria

Inclusion Criteria

  • All lymphoma survivors who meet the inclusion criteria of the P11CHT study or
  • the CRYSTAL cohort study are eligible for the CRYSTAL case\-control study. The
  • most important inclusion criteria for the P11CHT and CRYSTAL cohort study are:
  • \* Diagnosis of Hodgkin's lymphoma (P11CHT) or aggressive B\-cell non\-Hodgkin's
  • lymphoma (CRYSTAL cohort)
  • \* Treatment for the lymphoma between 1965 and 2005 (P11CHT) or between 1989 and
  • 2012 (CRYSTAL cohort)
  • \* Age at diagnosis \<51 years (P11CHT) or \<61 years (CRYSTAL cohort)
  • \* Still alive at least 5 years after primary lymphoma treatment

Exclusion Criteria

  • \* A history of (symptomatic) myocardial infarction, valvular heart disease,
  • cardiomyopathy or heart failure before lymphoma diagnosis
  • \* Chemotherapy or immunotherapy for a primary malignancy before lymphoma
  • \* Radiotherapy to the trunk before lymphoma diagnosis
  • \* Myocardial infarction or \*CTCAE grade 2 valvular heart disease prior to
  • diagnosis of cardiomyopathy or heart failure
  • \* Insufficient understanding of the Dutch language (for survivors receiving the
  • questionnaire)

Outcomes

Primary Outcomes

Not specified

Similar Trials